Eisai establishes a European strategic business hub in the U.K.
Eisai Europe Ltd. , a regional headquarter in Europe and a subsidiary of Eisai Co., Ltd. concluded the Heads of Terms with Arlington Securities Ltd. in the U.K. on land sales and the development to establish a strategic business hub in Europe. Eisai will consolidate the internal functions including discovery research, clinical development, production, sales and headquarters operations in Europe in this place to establish a strategic business hub which will be a center of business activities across Europe.
The site Eisai concluded the Heads of Terms this time is about 14.6 acres of land in the Hatfield Business Park located in the northern London and a new manufacturing subsidiary with plants will be built here. The construction will be started in 2006 and Eisai Europe Ltd., an existing regional headquarter in Europe, and Eisai Ltd., a subsidiary of clinical research and sales, will be sequentially relocated to this site. Further adding a discovery research function to the site to expand and strengthen Eisai London Research Laboratories, Ltd., a subsidiary of discovery research located at the University of London (UCL), the first production and research activities for drug discovery will be started in 2008. Eisai assumes that total invested amount including cost for purchasing the land will be approx. 15 billion yen. Furthermore, establishment of the hub will create more than 500 jobs in total including new employment of 300 employees in the Hatfield Business Park.
Eisai has already set up sales subsidiaries in major regions of Europe including the U.K., Germany, France, Spain, Italy, Switzerland and Sweden to improve the sales structure of our pharmaceutical products. Eisai will strive to accelerate the expansion of our business with a comprehensive view of all over the Europe, enhance satisfaction of patients and contribute to the improvement of benefits of more patients in Europe in the future.
Other news from the department business & finance
